智通财经APP获悉，香港联交所最新数据显示，11月19日，非执行董事郭华清增持科济药业- B(02171)3.65万股，每股作价17.29港元，总金额约为63.11万港元。增持后最新持股数目约为2.182亿 股，持股比例为37.75%。 ...

Core Insights - CAR-T therapy represents a revolutionary breakthrough in cancer treatment, enabling T cells to precisely identify and attack cancer cells [2] - Kintor Pharmaceutical's Shu Rui Ji Ao Lun Sai injection is poised to become the world's first CAR-T product approved for treating solid tumors, specifically targeting advanced gastric/esophageal junction adenocarcinoma [3][4] - The company is optimistic about the market potential for Shu Rui Ji Ao Lun Sai, especially given the significant unmet clinical needs in advanced gastric cancer treatment [3][4] Company Developments - Kintor Pharmaceutical's Shu Rui Ji Ao Lun Sai injection has received acceptance for new drug listing, with ongoing clinical research for indications beyond gastric cancer, including high-risk pancreatic cancer [4] - The company plans to independently commercialize Shu Rui Ji Ao Lun Sai, despite interest from multiple pharmaceutical companies for collaboration, and is currently building its commercialization team [4] - The injection has received RMAT designation from the FDA, and Kintor intends to collaborate with distributors for overseas sales [4] Industry Trends - The CAR-T market currently lacks approved products for solid tumors, with existing therapies primarily focused on hematological malignancies [3] - The high cost of CAR-T therapies, approximately 1 million yuan per treatment, limits accessibility, but recent policy changes may improve the situation through commercial health insurance [5] - Kintor is developing a universal CAR-T product to address cost and accessibility issues, aiming to reduce production costs to the range of thousands of yuan [5][6] Technological Innovations - Kintor has developed the THANK-uCAR and THANK-u Plus technology platforms to mitigate the risk of rejection associated with universal CAR-T therapies [6] - Clinical data for the second-generation universal CAR-T product CT0596 shows promising results, with a significant percentage of patients achieving partial or complete remission [6] - The company is exploring various universal CAR-T candidates targeting multiple antigens, including CLDN18.2, GPC3, and CD19/CD20, to expand treatment options [6]

转自：新华财经 科济药业联合创始人、COO王华茂则从产业落地层面介绍了公司的产能建设与生产工艺优化战略。据其介绍，未来将进一步打造涵盖自体与异体CAR-T细 胞制造能力的一体化智能细胞制造中心，预计设计产能将提升至每年数万人份，大幅提升产品供应能力。 "未来我们将聚焦工艺自动化、管理信息化和产业链协同化三大方向，持续降低生产成本、提升产品质量，让CAR-T疗法更易被患者获得。"王华茂强调，科 济药业的最终目标是助力中国CAR-T产业实现"全球领跑"，为更多癌症患者带来治愈希望。 近年来，BD（商务合作与授权）交易数量迎来爆发式增长，此类交易已成为生物制药企业重要的收入来源，这一合作议题也因此成为投资机构关注的焦 点。科济药业回应投资机构表示，BD合作的核心取决于产品竞争力、企业实力及能否满足合作方需求，而非单纯的外部环境因素。科济药业深耕细胞治疗 领域11年，与多家跨国公司（MNC）保持良好合作关系，如今已具备硬核产品、优质平台和稳健现金流的优势。 对于BD策略，科济药业表示其更偏向长期价值导向。"得益于稳健的发展态势，我们无需'卖青苗'求生存，在BD决策上拥有充足的灵活空间。BD工作的核 心目的是为公司发展 ...

科济药业-B(02171)发布公告，于2025年11月20日斥资297.44万港元回购16.8万股股份。 ...

格隆汇11月20日丨科济药业-B(02171.HK)公告，11月20日耗资298万港元回购16.8万股。 ...

智通财经APP讯，科济药业-B(02171)发布公告，于2025年11月20日斥资297.44万港元回购16.8万股股 份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 科濟藥業控股有限公司 呈交日期： 2025年11月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02171 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有 ...

截至发稿，百济神州(06160.HK)涨4.36%、药捷安康-B(02617.HK)涨3.77%、科济药业-B(02171.HK)涨 1.89%。 ...

Core Viewpoint - Cancer immunotherapy is emerging as a key treatment method for cancer, following surgery, radiotherapy, and chemotherapy, and is expected to see significant market growth in the coming years [1][6][7]. Group 1: Industry Definition and Classification - Cancer immunotherapy aims to activate or enhance the immune system to target tumor cells, utilizing methods such as cytokine therapy, cancer vaccines, T-cell therapy, and immune checkpoint inhibitors [2][4]. Group 2: Current Development Status - Cancer remains a leading health threat, with over 10 million deaths annually. The global anti-cancer drug market is projected to grow from $150.3 billion in 2020 to $253.3 billion in 2024, with cancer immunotherapy expected to reach $69.91 billion, accounting for 27.60% of the market [4][6][7]. Group 3: Industry Chain - The cancer immunotherapy industry chain includes upstream activities such as basic research and drug design, midstream development and production, and downstream medical institutions and testing agencies [8]. Group 4: Development Environment and Policies - Cancer is the leading cause of death globally, with a low early diagnosis rate in China. The government has implemented policies to enhance cancer prevention and treatment, such as the "Healthy China Action - Cancer Prevention and Control Action Implementation Plan (2023-2030)" [9]. Group 5: Competitive Landscape - The cancer immunotherapy market is characterized by concentrated leadership and technological differentiation, with key players including Legend Biotech, Akeso, I-Mab, Junshi Biosciences, and others. Notable advancements have been made in CAR-T, bispecific antibodies, and NK therapies [10][11]. Group 6: Future Development Directions - While cancer immunotherapy has transitioned from laboratory concepts to clinical practice, challenges such as resistance, toxicity, and accessibility remain. Future advancements may lead to a shift from "prolonging survival" to "functional cure" through interdisciplinary innovation and policy support [12][13].

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 17, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks [1]. Group 1: Buyback Details - China Feihe (06186) repurchased 10.81 million shares for a total of 47.19 million yuan, representing 1.532% of its total share capital [2]. - COSCO Shipping Holdings (01919) repurchased 3 million shares for 41.62 million yuan, accounting for 1.083% of its total share capital [2]. - Sinopec Limited (00386) repurchased 3.79 million shares for 16.73 million yuan, which is 0.120% of its total share capital [2]. Group 2: Other Notable Buybacks - Lianlian Digital (02598) repurchased 1.71 million shares for 13.67 million yuan, representing 2.608% of its total share capital [2]. - Linklogis Technology (09959) repurchased 2.65 million shares for 7.40 million yuan, accounting for 4.885% of its total share capital [2]. - Jitu Express (01519) repurchased 640,000 shares for 6.25 million yuan, which is 0.041% of its total share capital [2]. Group 3: Additional Companies - Mengniu Dairy (02319) repurchased 200,000 shares for 2.98 million yuan, representing 0.660% of its total share capital [2]. - Kangning Jereh Pharmaceutical (09966) repurchased 350,000 shares for 3.42 million yuan, accounting for 0.211% of its total share capital [3]. - Huajian Medical (01931) repurchased 593,000 shares for 3.64 million yuan, which is 0.660% of its total share capital [3].